

Important Notice Regarding the Proton Pump Inhibitors (including Nexium®, Prevacid®, Losec®) Class Action (Ontario Superior Court of Justice Court File No. CV-17-578782-00CP)

On July 12, 2017, Douglas Carter and Calvin Jessome (the “**Plaintiffs**”) commenced a proposed class proceeding against AstraZeneca Canada Inc., BGP Pharma ULC, Mylan Pharmaceuticals ULC, and Takeda Pharmaceuticals America Inc. (the “**Defendants**”). The proposed class proceeding involved proton pump inhibitor prescription medicines marketed by the Defendants (including Nexium®, Prevacid®, and Losec®). The Defendants deny all of the allegations made against them in the proceeding.

The proceeding was never certified as a class action. As the matter has not advanced since the claim was filed, the Ontario Superior Court of Justice has ordered that, effective December 31, 2021, the proceeding is dismissed for delay pursuant to s. 29.1 of the *Class Proceedings Act, 1992*.

YOU SHOULD TAKE NOTICE THAT while this proposed class action was pending, limitation periods (time limits) for starting individual actions in Ontario against the Defendants were suspended. Those limitation periods will begin running again as of December 31, 2021. Upon the expiry of a limitation period, you may lose any right you might have had to sue. If you wish to pursue your own action against the Defendants, you should consult with your own lawyer, as you may need to take steps to protect your rights.

If you have any questions about any of the information in this notice, please contact Merchant Law Group (<http://www.merchantlaw.com>) or call 306-359-7777.

This notice has been approved by the Ontario Superior Court of Justice.